• CBT-102 is a potent inhibitor of the MAP Kinase pathway by affecting b-RAF and c-RAF kinases as well as an inhibitor of angiogenesis by affecting the VEGF and PDGF receptors.
  • CBT-102 has shown broad and potent antitumor activity in patient derived xenografts of liver cancer, breast cancer, colorectal cancer, and non small cell lung cancer models. It has excellent oral bioavailability and biopharmaceutical properties, and an well tolerated safety profile in a chronic safety study.
  • CBT Pharmaceuticals retain retain world-wide rights to this program.